Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
UBQLN2 Antibody (monoclonal) (M03)
Mouse monoclonal antibody raised against a partial recombinant UBQLN2.
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, IF |
|---|---|
| Primary Accession | Q9UHD9 |
| Other Accession | NM_013444 |
| Reactivity | Human, Mouse, Rat |
| Host | mouse |
| Clonality | Monoclonal |
| Isotype | IgG2a Kappa |
| Clone Names | 5F5 |
| Calculated MW | 65696 Da |
| Gene ID | 29978 |
|---|---|
| Other Names | Ubiquilin-2, Chap1, DSK2 homolog, Protein linking IAP with cytoskeleton 2, PLIC-2, hPLIC-2, Ubiquitin-like product Chap1/Dsk2, UBQLN2, N4BP4, PLIC2 |
| Target/Specificity | UBQLN2 (NP_038472, 555 a.a. ~ 624 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
| Dilution | WB~~1:500~1000 |
| Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
| Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
| Precautions | UBQLN2 Antibody (monoclonal) (M03) is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes an ubiquitin-like protein (ubiquilin) that shares high degree of similarity with related products in yeast, rat and frog. Ubiquilins contain a N-terminal ubiquitin-like domain and a C-terminal ubiquitin-associated domain. They physically associate with both proteasomes and ubiquitin ligases; and thus, are thought to functionally link the ubiquitination machinery to the proteasome to affect in vivo protein degradation. This ubiquilin has also been shown to bind the ATPase domain of the Hsp70-like Stch protein.
References
1.C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking.Farg MA, Sundaramoorthy V, Sultana JM, Yang S, Atkinson RA, Levina V, Halloran MA, Gleeson PA, Blair IP, Soo KY, King AE, Atkin JDHum Mol Genet. 2014 Feb 27.2.Lower Motor Neuron Involvement in TAR DNA-Binding Protein of 43 kDa-Related Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis.Riku Y, Watanabe H, Yoshida M, Tatsumi S, Mimuro M, Iwasaki Y, Katsuno M, Iguchi Y, Masuda M, Senda J, Ishigaki S, Udagawa T, Sobue GJAMA Neurol. 2013 Dec 30. doi: 10.1001/jamaneurol.2013.5489.3.Progressive amnestic dementia, hippocampal sclerosis, and mutation in C9ORF72.Murray ME, Bieniek KF, Banks Greenberg M, Dejesus-Hernandez M, Rutherford NJ, van Blitterswijk M, Niemantsverdriet E, Ash PE, Gendron TF, Kouri N, Baker M, Goodman IJ, Petrucelli L, Rademakers R, Dickson DWActa Neuropathol. 2013 Aug 7.4.Ubiquilin-1 immunoreactivity is concentrated on Hirano bodies and dystrophic neurites in Alzheimer's disease brains.Satoh J, Tabunoki H, Ishida T, Saito Y, Arima KNeuropathol Appl Neurobiol. 2013 Feb 20. doi: 10.1111/nan.12036.5.Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion.Bieniek KF, Murray ME, Rutherford NJ, Castanedes-Casey M, Dejesus-Hernandez M, Liesinger AM, Baker MC, Boylan KB, Rademakers R, Dickson DW.Acta Neuropathol. 2012 Sep 28. [Epub ahead of print]6.p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS.Al-Sarraj S, King A, Troakes C, Smith B, Maekawa S, Bodi I, Rogelj B, Al-Chalabi A, Hortobagyi T, Shaw CE.Acta Neuropathol. 2011 Dec;122(6):691-702. Epub 2011 Nov 19.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
